EUVIMEDEUVIMED entdecken
Crossref

Transformer-Based Deep-Learning Model for Predicting Hemoglobin Response to Mircera® in Hemodialysis Patients

Siwei Zhao, Yunfei Luo, Joseph Mahaffy, Subhasis Dasgupta, Armin Ahmadi, Jerome Tannenbaum, Tauhidur Rahman, Rakesh Malhotra

Blood Purification · 08.07.2026 · 1-11

DOI: 10.1159/000552078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Purification, online erschienen am 08.07.2026. Verfasst von Siwei Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sanderling Renal Services, Nashville, Tennessee, USA. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Anemia management in hemodialysis (HD) depends on individualized erythropoiesis-stimulating agent (ESA) dosing to achieve and maintain target hemoglobin (Hgb) levels. However, predicting individual Hgb responses remains a significant challenge due to nonlinear erythropoietic dynamics and patient heterogeneity. We developed a machine learning-based approach to predict individual Hgb response to ESA therapy in HD patients.

Methods

We included adult patients undergoing HD at Sanderling clinics who received intravenous (IV) ESA (Mircera®) and IV elemental iron and had ≥5 qualifying dosing events with associated post-dose Hgb measurements. Clinical, dialysis, and laboratory data were structured into an event-based dataset, where each event included pre-dose Hgb, contemporaneous Mircera® and iron doses, and follow-up Hgb 7–21 days later. Pharmacokinetically informed features, including cumulative and time-weighted Mircera® dosing, were engineered to capture delayed erythropoietic effects. A transformer-based neural network was trained using sequences of five consecutive events. Model performance was assessed using a patient-level train-test split, with mean absolute percentage error (MAPE) as the primary metric. The MAPE was calculated as the average absolute percentage error between the predicted future Hgb and the observed future Hgb. To illustrate clinical utility, we conducted simulation-based forecasting of 30-day Hgb trajectories under varying hypothetical Mircera® doses (0–200 µg) in 4 representative patients. In addition, simulation error was summarized at the cohort level across all eligible patients to assess overall forecasting performance under hypothetical dosing scenarios.

Results

Among 728 HD patients, the mean age was 63 ± 14 years, with dialysis vintage 2.1 ± 1.8 years. Of these, 43% were female and 40% had diabetes. Patients received 114 ± 56 mg/week of IV iron and 149 ± 92 µg/month of IV Mircera®. Mean Hgb was 10.1 ± 0.9 g/dL, transferrin saturation (TSAT) 31 ± 10%, and ferritin level 703 ± 452 ng/mL. The transformer model predicted future Hgb with a MAPE of ∼6.0%. Simulation-based forecasting in representative patients, together with cohort-level summary of simulation error (MAPE 6.29%), demonstrated the model’s ability to project individualized Hgb trajectories under varying Mircera® dosing scenarios.

Conclusion

Our results showed the promising performance of a transformer-based machine learning model in predicting future Hgb levels within 6% of observed levels in HD patients being treated with Mircera® and IV iron. These findings suggest the potential for personalized ESA dosing strategies informed by sequential clinical data. Future studies should focus on refining these models and evaluating their real-world clinical utility with the goal of personalized ESA dosing to maximize on-target Hgb levels.

Schlagwörter

Stichwörter der Autor:innen

AnemiaHemodialysisHemoglobinMachine learningMircera dosing

Autor:innen und Institutionen

  • Sanderling Renal Services, Nashville, Tennessee, USA.
  • Halıcıoğlu Data Science Institute, University of California San Diego, San Diego, California, USA.
  • Department of Mathematics, San Diego State University, San Diego, California, USA.
  • San Diego Supercomputer Center, University of California San Diego, San Diego, California, USA.
  • Division of Nephrology-Hypertension, University of California San Diego, San Diego, California, USA.
  • Division of Nephrology-Hypertension, University of California San Diego, San Diego, California, USA, r3malhotra@health.ucsd.edu.

Zitieren

APA

Zhao, S., Luo, Y., Mahaffy, J., Dasgupta, S., Ahmadi, A., Tannenbaum, J., Rahman, T., & Malhotra, R. (2026). Transformer-Based Deep-Learning Model for Predicting Hemoglobin Response to Mircera® in Hemodialysis Patients. Blood Purification, 1-11. https://doi.org/10.1159/000552078

Vancouver

Zhao S, Luo Y, Mahaffy J, Dasgupta S, Ahmadi A, Tannenbaum J, et al. Transformer-Based Deep-Learning Model for Predicting Hemoglobin Response to Mircera® in Hemodialysis Patients. Blood Purification. 2026:1-11. doi:10.1159/000552078

BibTeX
@article{Zhao2026,
  author = {Zhao, Siwei and Luo, Yunfei and Mahaffy, Joseph and Dasgupta, Subhasis and Ahmadi, Armin and Tannenbaum, Jerome and Rahman, Tauhidur and Malhotra, Rakesh},
  title = {Transformer-Based Deep-Learning Model for Predicting Hemoglobin Response to Mircera® in Hemodialysis Patients},
  journal = {Blood Purification},
  year = {2026},
  pages = {1--11},
  doi = {10.1159/000552078}
}
Kostenlos starten →